Sanofi (STU:SNW) Cash from Discontinued Operating Activities: €189 Mil (TTM As of Dec. 2025)


STU:SNW Sanofi SA STU:SNW
87 GF Score
Price €73.65
GF Value €107.22
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Sanofi Cash from Discontinued Operating Activities?

Sanofi STU:SNW +0.95% 87 Cash from Discontinued Operating Activities is €189 Mil as of Dec. 2025. GuruFocus rates STU:SNW with a GF Score™ of 87/100 and a GF Value™ of €107.22 (Possible Value Trap). The stock has 2 warning signs investors should review.

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Sanofi's Cash from Discontinued Operating Activities for the six months ended in Dec. 2025 was €1 Mil. It means Sanofi received €1 Mil from discontinued investing activities. Sanofi's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Dec. 2025 was €189 Mil.

Sanofi Cash from Discontinued Operating Activities Related Terms

Sanofi Cash from Discontinued Operating Activities Historical Data

* Premium members only.

The historical data trend for Sanofi's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Cash from Discontinued Operating Activities Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash from Discontinued Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 888.00 987.00 474.00 189.00

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash from Discontinued Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 184.00 290.00 188.00 1.00
STU:SNW
87GF Score
Sanofi SA STU:SNW
Cash from Discontinued Operating Activities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €189 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash from Discontinued Operating Activities of €189 Mil mean?
Sanofi (STU:SNW) has a Cash from Discontinued Operating Activities of €189 Mil as of Dec. 2025. Cash Flow from Discontinued Operating Operations is the amount of cash earned from operating operations in ceased business operations. View historical data for Sanofi and its competitors.
Is Sanofi's Cash from Discontinued Operating Activities too high?
Sanofi's current Cash from Discontinued Operating Activities is €189 Mil. Overall, Sanofi has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Cash from Discontinued Operating Activities compare to LLY and JNJ?
Sanofi's Cash from Discontinued Operating Activities of €189 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash from Discontinued Operating Activities for a Drug Manufacturers company?
A good Cash from Discontinued Operating Activities depends on the Drug Manufacturers industry context. However, Cash from Discontinued Operating Activities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash from Discontinued Operating Activities mean?
A high Cash from Discontinued Operating Activities can signal that a stock is expensive relative to its fundamentals. Cash Flow from Discontinued Operating Operations is the amount of cash earned from operating operations in ceased business operations. View historical data for Sanofi and its competitors. Sanofi's current Cash from Discontinued Operating Activities is €189 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (STU:SNW) is currently considered Possible Value Trap. The stock's GF Value™ is €107.22, compared to a current price of €73.65 — trading 31.3% below its estimated fair value. The current Cash from Discontinued Operating Activities is €189 Mil. Sanofi's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash from Discontinued Operating Activities calculated?
Cash from Discontinued Operating Activities is calculated from a company's financial statements. For Sanofi (STU:SNW), the current Cash from Discontinued Operating Activities is €189 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (STU:SNW) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of €73.65 is trading 31.3% below its estimated GF Value™ of €107.22. GuruFocus considers Sanofi to be Possible Value Trap.

Key valuation signals for STU:SNW:

  • Cash from Discontinued Operating Activities: €189 Mil
  • GF Value™: €107.22 vs. price of €73.65 (31.3% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the STU:SNW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score

Get the complete analysis for STU:SNW

Cash from Discontinued Operating Activities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.65
Price
€107.22
GF Value